PRNewsWire
22 Aug 2026, 20:00 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Alnylam Pharmaceuticals reduced its full-year 2026 TTR net product revenue guidance by approximately $200 million. — A significant downward revision in revenue guidance for a core product directly hits valuation and indicates slowing growth.
-0.80Alnylam's stock price declined by over 28% following the announcement of its second quarter 2026 financial results. — While the drop has already occurred, the scale of the sell-off confirms strong negative market sentiment and a loss of investor confidence.
-0.50Law firm Kessler Topaz Meltzer & Check is investigating Alnylam for potential violations of federal securities laws. — The initiation of a securities fraud investigation creates legal overhang and potential future liability for the company.
-0.30Continue reading
6 related stories
Top 1 mover · tap to explore
The revenue guidance cut was driven by a normalization of growth in second-line volume after initial pent-up demand was satisfied. — This suggests that the initial growth spurt was temporary rather than sustainable, lowering long-term growth expectations.
-0.20Which stocks this story touches
The company lowered revenue guidance, suffered a stock price drop of over 28%, and is facing a securities fraud investigation.
The company is mentioned as being subject to a securities fraud class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
12h ago
